Resmed's Matrixcare Sale May Hint at AI Disruption Risk

Dow Jones12:09

0409 GMT - ResMed's sale of its MatrixCare business at a lower-than-expected earnings multiple leads RBC analyst Craig Wong-Pan to suspect that the breath-tech maker may have been worried about AI disruption risks. Wong-Pan didn't expect a sale to match the 25X earnings ResMed paid in 2018, but had anticipated a multiple in the low double digits to mid teens. Instead, ResMed is selling at 8.9X earnings. He expects the majority of the US$490 million proceeds to be distributed to shareholders. "We wonder if ResMed's decision to sell at this multiple partly reflects possible risks of future AI disruption to its software business." RBC has an outperform rating and US$321.00 target price on ResMed's U.S.-listed stock. Its ASX-listed shares are down 0.5% at 31.29 Australian dollars. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

July 08, 2026 00:09 ET (04:09 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649952059?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 12:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649952059","market":"nz","top_or_hot":-1,"title":"Resmed's Matrixcare Sale May Hint at AI Disruption Risk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0409 GMT - ResMed's sale of its MatrixCare business at a lower-than-expected earnings multiple leads RBC analyst Craig Wong-Pan to suspect that the breath-tech maker may have been worried about AI disruption risks. Wong-Pan didn't expect a sale to match the 25X earnings ResMed paid in 2018, but had anticipated a multiple in the low double digits to mid teens. Instead, ResMed is selling at 8.9X earnings. He expects the majority of the US$490 million proceeds to be distributed to shareholders. \"We wonder if ResMed's decision to sell at this multiple partly reflects possible risks of future AI disruption to its software business.\" RBC has an outperform rating and US$321.00 target price on ResMed's U.S.-listed stock. Its ASX-listed shares are down 0.5% at 31.29 Australian dollars. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 00:09 ET (04:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Resmed's Matrixcare Sale May Hint at AI Disruption Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResmed's Matrixcare Sale May Hint at AI Disruption Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-08 12:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0409 GMT - ResMed's sale of its MatrixCare business at a lower-than-expected earnings multiple leads RBC analyst Craig Wong-Pan to suspect that the breath-tech maker may have been worried about AI disruption risks. Wong-Pan didn't expect a sale to match the 25X earnings ResMed paid in 2018, but had anticipated a multiple in the low double digits to mid teens. Instead, ResMed is selling at 8.9X earnings. He expects the majority of the US$490 million proceeds to be distributed to shareholders. \"We wonder if ResMed's decision to sell at this multiple partly reflects possible risks of future AI disruption to its software business.\" RBC has an outperform rating and US$321.00 target price on ResMed's U.S.-listed stock. Its ASX-listed shares are down 0.5% at 31.29 Australian dollars. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 00:09 ET (04:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2008162690.USD","symbol_name":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649952059","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649952059","pubTimestamp":1783483740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0409 GMT - ResMed's sale of its MatrixCare business at a lower-than-expected earnings multiple leads RBC analyst Craig Wong-Pan to suspect that the breath-tech maker may have been worried about AI disruption risks. Wong-Pan didn't expect a sale to match the 25X earnings ResMed paid in 2018, but had anticipated a multiple in the low double digits to mid teens. Instead, ResMed is selling at 8.9X earnings. He expects the majority of the US$490 million proceeds to be distributed to shareholders. \"We wonder if ResMed's decision to sell at this multiple partly reflects possible risks of future AI disruption to its software business.\" RBC has an outperform rating and US$321.00 target price on ResMed's U.S.-listed stock. Its ASX-listed shares are down 0.5% at 31.29 Australian dollars.  Dow Jones NewswiresJuly 08, 2026 00:09 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2008162690.USD":"FIDELITY FUNDS - ASIA PACIFIC OPPORTUNITIES \"A\" (USD) ACC","AIPO":"Defiance AI and Power Infrastructure ETF","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4082":"医疗保健设备","BK4504":"桥水持仓","ARTY":"ISHARES FUTURE AI & TECH ETF","QTOC":"Innovator Growth Accelerated Plus ETF - October","BK4588":"碎股","LU2177674079.SGD":"Fidelity Asia Pacific Opportunities A-ACC-SGD (hedged)","RMD.AU":"Resmed DRC","BK4548":"巴美列捷福持仓","RMD":"瑞思迈","AGIX":"通用人工智能 ETF-AGIX","IE00B5TLWC47.USD":"BNY MELLON LONG-TERM GLOBAL EQUITY \"B\" (USD) ACC","LGHT":"LANGAR GLOBAL HEALTHTECH ETF","BK7501":"新冠治疗股","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK7007":"医疗保健设备","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","VTHR":"Vanguard Russell 3000 ETF"},"translate_title":"瑞思迈出售Matrixcare可能暗示人工智能颠覆风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":0.9,"AGIX":1.5,"RMD.AU":0.9,"LGHT":0.6,"QTOC":1.5,"ARTY":1.5,"AIPO":1.5,"CHAT":1.5,"VTHR":1.5},"content_text":"0409 GMT - ResMed's sale of its MatrixCare business at a lower-than-expected earnings multiple leads RBC analyst Craig Wong-Pan to suspect that the breath-tech maker may have been worried about AI disruption risks. Wong-Pan didn't expect a sale to match the 25X earnings ResMed paid in 2018, but had anticipated a multiple in the low double digits to mid teens. Instead, ResMed is selling at 8.9X earnings. He expects the majority of the US$490 million proceeds to be distributed to shareholders. \"We wonder if ResMed's decision to sell at this multiple partly reflects possible risks of future AI disruption to its software business.\" RBC has an outperform rating and US$321.00 target price on ResMed's U.S.-listed stock. Its ASX-listed shares are down 0.5% at 31.29 Australian dollars. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2026 00:09 ET (04:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649952059","isCrawlerRequest":true}